menu
    • menu
    [{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YourChoice Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"YourChoice Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"YourChoice Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"YourChoice Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by YourChoice Therapeutics

    Menu

    YourChoice Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    YourChoice Therapeutics

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    YourChoice Therapeutics

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : YCT529

    Therapeutic Area : Endocrinology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    YourChoice Therapeutics Begins Second Human Study For Hormone-Free Male Birth Control Pill

    Details : YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under early-stage clinical development for male contraception.

    Product Name : YCT529

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 24, 2024

    Lead Product(s) : YCT529

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    YourChoice Therapeutics

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    YourChoice Therapeutics

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : YCT529

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    YourChoice Completes Phase 1a Study Of First Hormone-Free Male Birth Control Pill

    Details : YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.

    Product Name : YCT529

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 06, 2024

    Lead Product(s) : YCT529

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    YourChoice Therapeutics

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    YourChoice Therapeutics

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : YCT529

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Study Phase : Phase I

    Sponsor : Quotient Sciences

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Quotient Sciences Supports YourChoice Therapeutics with Phase I Trial of Novel Hormone-Free Male Birth Control...

    Details : YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.

    Product Name : YCT529

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 13, 2023

    Lead Product(s) : YCT529

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Phase I

    Sponsor : Quotient Sciences

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth